

Heart valve disease Committee meeting 14

Date: 20/11/2020

Location: Virtual meeting via Zoom

Minutes: Confirmed

Committee members present:	
Norman Briffa (NB)	(Present for notes 1 – 5)
Joy Ellery (JE)	(Present for notes 1 – 5)
Madalina Garbi (MG)	(Present for notes 1 – 5)
Marjan Jahangiri (MJ)	(Present for notes 1 – 5)
Muhammad Murad Khan (MMK)	(Present for notes 1 – 5)
Rajesh Kharbanda (RKK)	(Present for notes 1 – 4)
Saul Myerson (SM)	(Present for notes 1 – 5)
Denise Parkin (DP)	(Present for notes 1 – 5)
Phil Smith (PS) (Chair)	(Present for notes 1 – 5)

In attendance:		
Victoria Axe (VA)	Guideline Commissioning Manager, NICE	(Present for notes 1 – 5)
Anne-Louise Clayton	Senior Medical Editor, NICE	(Present for notes 1 – 5)
Nicole Downes (ND)	Systematic Reviewer, NGC	(Present for notes 1 – 5)
Shama Mahammed (SMa)	Health Economist, NGC	(Present for notes 1 – 5)
Alfredo Mariani (AM)	Health Economist, NGC	(Present for notes 1 – 5)
Eleanor Samarasekera (ES)	Senior Research Fellow, NGC	(Present for notes 1 – 5)
Sharon Swain (SS)	Guideline Lead, NGC	(Present for notes 1 – 5)
Katie Tuddenham (KT)	Project Manager, NGC	(Present for notes 1 – 5)
David Wonderling (DW)	Head of Health Economics, NGC	(Present for notes 1 – 5)

Apologies:	
Suzannah Power (SP)	Guideline Committee
Simon Ellis (SE)	Associate Director for Commissioning, NICE

1. Welcome and objectives for the meeting

PS welcomed the Committee members and attendees to the fourteenth meeting of the Heart Valve Disease guideline. The Committee members and attendees introduced themselves.

PS informed the Committee that apologies had been received (noted above).

PS outlined the objectives of the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The DOI register was made available to PS. PS reviewed the DOI register and deemed that two committee members had DOIs that were in conflict with the agenda topics under discussion at this meeting:

- MG for indications for interventions for people with asymptomatic aortic stenosis.
- SM for MRI for mitral regurgitation.

PS used his discretion to ensure that these committee members were not influencing the recommendations for the areas listed.

PS also asked everyone to verbally declare any interests that have arisen since the last meeting. The following new interests were received for this committee meeting:

Committee Declarations of Interest

N.B. The Committee members were recruited to this guideline using NICE DOI policy published April 2018.

Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
MG	<p>British Society of Echocardiography Annual Conference invited speaker on "Differential diagnosis of the right heart dilatation"</p> <p>British Heart Valve society annual conference invited speaker on "Mitral valve prolapse, what does the surgeon need to know"</p>	<p>Direct non-financial non-specific</p> <p>Direct non-financial specific</p>	<p>No action other than the process of open declaration</p> <p>No action other than the process of open declaration</p>

	Publication in the Journal of the American College of Cardiology” – Invited Editorial “Arrhythmia in Mitral Valve Prolapse”	Direct non-financial non-specific	No action other than the process of open declaration
	Brief communication in the European Heart Journal to announce the electronic publication of the Heart Valve Specialist Core Syllabus	Direct non-financial specific	No action other than the process of open declaration
	ESC website publication of the ESC Heart Valve Specialist Core Syllabus	Direct non-financial specific	No action other than the process of open declaration

NICE DOI policy classifications are:

- Direct financial specific
- Direct financial non-specific
- Direct non-financial specific
- Direct non-financial non-specific
- Indirect financial specific
- Indirect financial non-specific

3. Minutes of the last meeting

The Committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentation and Discussion

4.1 AM gave a presentation on updates to the TMVR model following QA. The committee discussed edits to the draft recommendations.

4.2 SMA gave a presentation of the health economic studies identified through re-run searches.

4.3 AM gave a presentation on the model results for TAVI.

4.4 ES gave a presentation on the clinical studies identified through re-run searches. The committee discussed edits to the draft recommendations.

5. Any other business

The group discussed next steps and agreed action points.

Date of next meeting: 15/12/2020